Compare Adaptive Biotechnologies Corp (ADPT) vs Progressive Corp (PGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Progressive Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Progressive Corp trades at $235.97 (market cap $136.47B). The key difference: Progressive Corp is far larger — about 41× Adaptive Biotechnologies Corp's market cap, and Progressive Corp pays a 5.93% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PGR | |
|---|---|---|
Market Cap | $3.33B | $136.47B |
Sector | Health | Financials |
52-Week High | $22.37 | $252.68 |
52-Week Low | $10.24 | $190.40 |
Enterprise Value | $3.19B | $144.69B |
Dividend Yield | — | 5.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Progressive (PGR) trades at $234.40, up 0.94% with a bullish technical signal and strong fundamentals. Recent earnings beat expectations with Q1 2026 EPS of $4.96 versus $4.85 estimate, continuing a trend of operational strength. Revenue grew to $87.64B in 2025 with net income margin at 12.93%, while analyst consensus price target is $235.67. The stock shows resilience with positive media coverage highlighting earnings growth and leadership changes.
Outlook remains positive driven by earnings momentum and scale advantages in auto insurance. Key risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed with 41.46% buy ratings, but the stock's valuation at P/E 11.78 offers room for upside if earnings trends persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
